Scripps Translational Science Institute

51 total trials 39 currently recruiting 5 completed

Trial Pipeline

RECRUITING NA

The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study

NCT06244940

RECRUITING NA

The Long COVID-19 Wearable Device Study

NCT05741112

RECRUITING

Research Framework Exploring Sleep Health

NCT05197738

RECRUITING

The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study

NCT04336020

RECRUITING NA

MyGeneRank: A Digital Platform for Next-Generation Genetic Studies

NCT03277365

RECRUITING

POWERMOM, A Healthy Pregnancy Research Community

NCT03085875

RECRUITING

Molecular Autopsy Study

NCT02168088

RECRUITING

The Healthy Elderly Longevity Cohort

NCT01004133

ACTIVE NOT RECRUITING Phase 2

The Long COVID Treatment Trial

NCT07128082

ACTIVE NOT RECRUITING

PRediction Of Glycemic RESponse Study

NCT04881019

ACTIVE NOT RECRUITING

Molecular and Morphologic Characterization of Circulating Endothelial Cells

NCT01005485

ACTIVE NOT RECRUITING

The Biorepository for Scripps Health

NCT01006239

ACTIVE NOT RECRUITING

Scripps Genomics Health Initiative

NCT00808587

ACTIVE NOT RECRUITING

The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

NCT00766948

ACTIVE NOT RECRUITING

Genomic Investigation of Cardiovascular Diseases

NCT00722748

COMPLETED

Scripps Tumorgraft Study

NCT01726699

COMPLETED NA

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

NCT01258764

COMPLETED

Human Tumor Sequencing Project

NCT01608230

COMPLETED

Scripps Polster Breast Care Center Investigational GeneBank

NCT00945464

COMPLETED

Genetic Investigation of Solid Tumors Cohort

NCT01005225

What the Pipeline for Scripps Translational Science Institute Shows

According to the ClinicalTrials.gov registry, Scripps Translational Science Institute is linked to 51 US clinical trials across every stage of research activity. Of those, 39 studies are currently recruiting — about 76% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 10% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Scripps Translational Science Institute reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Scripps Translational Science Institute is Long COVID with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial